Home > Insider Trading > Filing (0001225208-25-001679)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
885725	Boston Scientific Corp	BSX	Surgical & Medical Instruments & Apparatus (3841)	042695240

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1595612	J. Daniel Brennan	300 Boston Scientific Way Marlborough MA 01752-1234	Evp And Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-02-11	33,944	$0.00	257,865	No	4	A	Direct
Common Stock	Disposition	2025-02-11	16,414	$105.98	241,451	No	4	F	Direct
Common Stock	Acquisiton	2025-02-12	15,087	$16.31	256,538	No	4	M	Direct
Common Stock	Disposition	2025-02-12	15,087	$105.07	241,451	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	F	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2025-02-12	15,087	$0.00	15,087	$16.31

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2025-02-23	No	4	M	Direct

Footnotes

On February 16, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2024 and subject to the completion of the concurrent three-year individual service period. On February 11, 2025, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.778 to $105.28, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.